Search results
CVS COVID-19 Vaccine Near Columbus OH
www.cvs.comPharmacy LocationBy appointment only3100 Cleveland Avenue(614) 263-092355 Graceland Blvd(614) 781-94073499 Clime Road(614) 276-26511485 Polaris Pkwy(614) 781-095060 North Stygler Road(614) 475-20145445 North High Street(614) 844-36992100 East Dublin Granville Road(614) 891-14104 days ago · Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital).
2 days ago · The ABRYSVO™ vaccine was approved by the U.S. FDA on August 21, 2023, as an alternative therapy for pregnant women between 32 and 36 weeks gestational age. In a subgroup of pregnant individuals who were 32 through 36 weeks gestational age, Pfizer Inc.'s Abrysvo reduced the risk of LRTD by 34.7% and the risk of severe LRTD by 91.1% within 90 ...
1 day ago · These results are part of the 3-year NIRSE-GAL study conducted in Galicia, Spain, and are from the first RSV season after the introduction of nirsevimab. The results reinforce other real-world evidence from several broad infant immunization programs in the US, Spain, and France during the 2023-2024 RSV season. 1
2 days ago · “Galicia provides the first population-based real-world evidence of the impact of nirsevimab to prevent RSV disease in infants, showing a reduction by almost 90% in the number of hospitalizations due to this virus when compared with several previous RSV seasons,” Federico Martinon Torres, MD, PhD, head of Pediatrics, Hospital Clínico ...
2 days ago · Ares-Gómez S, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a ...
2 days ago · These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain under a collaborative framework with the Galician Directorate of Public Health of the Xunta de Galicia (Galician government) and Sanofi. 1
2 days ago · Federico Martinon Torres Head of Pediatrics, Hospital Clínico Universitario Santiago, Spain and principal investigator of NIRSE-GAL study “Galicia provides the first population-based real-world evidence of the impact of nirsevimab to prevent RSV disease in infants, showing a reduction by almost 90% in the number of hospitalizations due to ...
